Subcutaneous (SC) Daratumumab (DARA) in Combination With Standard Multiple Myeloma (MM) Treatment Regimens: An Open-label, Multicenter Phase 2 Study (PLEIADES)

Subcutaneous (SC) Daratumumab (DARA) in Combination With Standard Multiple Myeloma (MM) Treatment Regimens: An Open-label, Multicenter Phase 2 Study (PLEIADES)

Saved in:
Bibliographic Details
Published in:Clinical lymphoma, myeloma and leukemia Vol. 19; no. 10; pp. e16 - e17
Main Authors: Chari, Ajai, Goldschmidt, Hartmut, San-Miguel, Jesus, McCarthy, Helen, Suzuki, Kenshi, Hungria, Vania, Balari, Anna Sureda, Perrot, Aurore, Hulin, Cyrille, Magen, Hila, Iida, Shinsuke, Maisnar, Vladimir, Karlin, Lionel, Pour, Ludek, Parasrampuria, Dolly, Masterson, Tara, Kosh, Michele, yang, shiyi, Qi, Ming, Carson, Robin, Moreau, Philippe
Format: Journal Article
Language:English
Published: Elsevier Inc 01-10-2019
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
ISSN:2152-2650
DOI:10.1016/j.clml.2019.09.023